RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
Proc. Natl. Acad. Sci. U.S.A., Feb;108(8):3336-41 (2011)
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.
N. Engl. J. Med., Jun;358(24):2585-93 (2008)
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
Mol. Cancer Res., May;6(5):735-42 (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature., Oct;455(7215):930-5 (2008)
Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Nature., Jan;469(7329):216-20 (2011)
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
Cancer Res., Apr;72(8):2068-78 (2012)
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
Clin. Cancer Res., May;18(9):2423-8 (2012)
An RNAi screen of the protein kinome identifies the cell cycle checkpoint kinase CHK1 as a therapeutic target in neuroblastoma
Proceedings of the National Academy of Science
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Copy number variation at 1q21.1 associated with neuroblastoma
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma